# ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding

> **NCT00616460** · PHASE3 · COMPLETED · sponsor: **HaEmek Medical Center, Israel** · enrollment: 100 (actual)

## Conditions studied

- Hematologic Diseases

## Interventions

- **DRUG:** Bivalirudin

## Key facts

- **NCT ID:** NCT00616460
- **Lead sponsor:** HaEmek Medical Center, Israel
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616460, "ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00616460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*